Regulatory Expectations for Cardiovascular Devices
Author
Marcel Dörkes, Senior Medical Device Consultant & Business Unit Manager - Medical Device Consulting Teams Germany & Benelux, Eurofins Medical Device Testing
Article
Cardiovascular devices, especially in long-term contact, are among the most highly regulated medical technologies due to their direct blood contact and the associated clinical risks. As regulatory bodies continue to strengthen expectations for biological safety, manufacturers must ensure their testing strategies align with updated standards.
ISO 10993-1 provides the overarching biological evaluation framework, defining the effects to be assessed based on device category, contact type, and clinical use. For blood-contacting medical devices, ISO 10993-4 expands this framework and specifies mandatory interaction categories for evaluating the potential risk for haemolysis and thrombosis.
Regulatory expectations revolve around a key principle: testing should exaggerate a worst‑case clinical scenario whilst still realistically reflecting the device’s clinical use. Striking this balance is essential, overly aggressive tests can distort results, whereas insufficient testing may overlook important safety concerns.
Eurofins implements these requirements through dynamic in vitro systems, fresh human blood, and high fidelity analytical markers that capture the complexity of blood–material interactions. Dynamic models, such as Chandler loops and agitation systems, simulate physiological shear stress, residence time, and geometry, enabling accurate evaluation of the five ISO 10993-4 endpoints.
Using fresh human blood supports realistic assessment of platelet activation, coagulation behaviour, haemolysis, and complement activation. Targeted ELISA assays and electron microscopy further strengthen this approach by providing quantitative and visual confirmation of cell and protein adhesion.
As regulators increasingly expect biological evaluations to be risk-based, clinically relevant, and aligned with state of the art ISO standards, manufacturers should reassess existing cardiovascular device files to confirm compliance. Proactive evaluation helps avoid delays in submissions and ensures continued market access.
Through dynamic testing systems and advanced analytical methods, Eurofins supports manufacturers in meeting the requirements of currently valid versions of ISO 10993-1, ISO 10993-4, and global regulatory authorities.